Skip to main content

Table 1 Clinical characteristics of BCLC very-early stage hepatocellular carcinoma patients before and after propensity scores matching

From: Clinical outcomes of surgical resection versus radiofrequency ablation in very-early‐stage hepatocellular carcinoma: a propensity score matching analysis

Characteristics

Study population before PSM

Study population after PSM

Total

SR group

RFA group

P-value

Total

SR group

RFA group

P-value

Patients

188

103

85

 

116

58

58

 

Age, years

59 (23–82)

57 (23–82)

62 (34–81)

0.006

61 (34–82)

61 (35–82)

61 (34–80)

0.788

Sex

        

Male

130(69.1)

75 (72.8)

55 (64.7)

0.299

78 (67.2)

39 (67.2)

39 (67.2)

1

Female

58 (30.9)

28 (27.2)

30 (35.3)

 

38 (32.8)

19 (32.8)

19 (32.8)

 

BMI

        

24 kg/m2

93 (49.5)

50 (48.5)

43 (50.6)

0.895

59 (50.9)

29 (50.0)

30 (51.7)

1

 > 24 kg/m2

95 (50.5)

53 (51.5)

42 (49.4)

 

57 (49.1)

29 (50.0)

28 (48.3)

 

Alcohol use

53 (28.2)

25 (24.33)

28 (32.9)

0.249

32 (27.6)

15 (25.9)

17 (29.3)

0.835

HBV

        

Positive

86 (45.7)

51 (49.5)

35 (41.2)

0.320

51 (44.0)

28 (48.3)

23 (39.7)

0.454

Negative

102 (54.3)

52 (50.5)

50 (58.8)

 

65 (56.0)

30 (51.7)

35 (60.3)

 

HCV

        

Positive

91(48.4)

49 (47.6)

42 (49.4)

0.917

61 (52.6)

34 (58.6)

27 (46.6)

0.265

Negative

97 (51.6)

54 (52.4)

43 (50.6)

 

55 (47.4)

24 (41.4)

31 (53.4)

 

Child‐Pugh class A

179 (95.2)

100 (97.1)

79 (92.9)

0.326

113 (97.4)

56 (96.6)

57(98.3)

1

Cirrhosis

115 (61.2)

54 (52.4)

61 (71.8)

0.011

72 (62.1)

36 (62.1)

36 (62.1)

1

Ascites

13 (6.9)

6 (5.8)

7 (8.2)

0.719

8 (6.9)

4 (6.9)

4 (6.9)

1

INR

1.0 (0.9–1.7)

1.0 (0.9–1.3)

1.1 (0.9–1.7)

 < 0.001

1.0 (0.9–1.7)

1.0 (0.9–1.3)

1.0 (0.9–1.7)

0.382

Total bilirubin, mg/dL

0.9 (0.2–5.4)

0.8 (0.2–5.4)

1.1 (0.3–4.2)

0.001

1.0 (0.3–3.9)

0.8 (0.5–3.9)

1.1 (0.3–4.2)

0.785

Albumin, g/dL

4.1 (2.5–4.9)

4.2 (3.2–4.9)

4.0 (2.5–4.7)

 < 0.001

4.1 (2.6–4.9)

4.1 (3.2–4.9)

4.0 (2.6–4.6)

0.051

ALBI grade 1

166 (88.3)

97 (94.2)

69 (81.2)

0.011

102 (87.9)

53 (91.4)

49 (84.5)

0.393

AFP > 200 ng/ml

29 (15.4)

12 (11.7)

17 (20.0)

0.169

17 (14.7)

5 (8.6)

12 (20.7)

0.115

Tumor size, cm

1.8 (1.0–2.0)

1.8 (1.0–2.0)

1.8 (1.0–2.0)

0.127

1.8(1.0–2.0)

1.9 (1.0–2.0)

1.8 (1.0–2.0)

0.875

Mortality

69 (36.7)

28 (27.2)

41 (48.2)

0.005

44 (37.9)

17 (29.3)

27 (46.6)

0.085

Recurrence

79 (42.0)

43 (41.7)

36 (42.4)

1.000

49 (42.2)

25 (43.1)

24 (41.4)

1.000

  1. Data shown as median (range) or number (%); PSM: propensity score matching; SR: Surgical resection; RFA: Radiofrequency ablation; BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; INR: international normalized ratio; ALBI: Albumin- bilirubin; AFP: Alpha-fetoprotein;